Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment.

Purpose: To assess the utility of measurement of the computed tomography (CT) attenuation value (CTav) in predicting tumor necrosis in hepatocellular carcinoma (HCC) patients who achieve a complete response (CR), defined using modified Response Evaluation Criteria in Solid Tumors (mRECIST), after le...

Descripción completa

Detalles Bibliográficos
Publicado en:Current Oncology Vol. 29; no. 5; pp. 3259 - 3272
Autores principales: Chuma, Makoto, Yokoo, Hideki, Hiraoka, Atsushi, Ueda, Kazuhiko, Yokoyama, Takahiro, Tsuji, Kunihiko, Shimada, Noritomo, Uojima, Haruki, Kobayashi, Satoshi, Hattori, Nobuhiro, Okubo, Tomomi, Atsukawa, Masanori, Ishikawa, Toru, Takaguchi, Koichi, Tsutsui, Akemi, Toyoda, Hidenori, Tada, Toshifumi, Saito, Yoshinori, Hirose, Shunji, Tanaka, Takaaki
Formato: Journal Article
Publicado: MDPI May2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157188013&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 157188013
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11980052
        5EKK
      jtl: Current Oncology
      issn: 11980052
      maglogo: N
    pubinfo:
      dt: May2022
      vid: 29
      iid: 5
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        157188013
        10.3390/curroncol29050266
        157188013
      ppf: 3259
      ppct: 13
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment.
      aug:
        au:
          Chuma, Makoto
          Yokoo, Hideki
          Hiraoka, Atsushi
          Ueda, Kazuhiko
          Yokoyama, Takahiro
          Tsuji, Kunihiko
          Shimada, Noritomo
          Uojima, Haruki
          Kobayashi, Satoshi
          Hattori, Nobuhiro
          Okubo, Tomomi
          Atsukawa, Masanori
          Ishikawa, Toru
          Takaguchi, Koichi
          Tsutsui, Akemi
          Toyoda, Hidenori
          Tada, Toshifumi
          Saito, Yoshinori
          Hirose, Shunji
          Tanaka, Takaaki
        affil: Gastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan
      sug:
      ab: Purpose: To assess the utility of measurement of the computed tomography (CT) attenuation value (CTav) in predicting tumor necrosis in hepatocellular carcinoma (HCC) patients who achieve a complete response (CR), defined using modified Response Evaluation Criteria in Solid Tumors (mRECIST), after lenvatinib treatment. Method: We compared CTav in arterial phase CT images with postoperative histopathology in four patients who underwent HCC resection after lenvatinib treatment, to determine CTav thresholds indicative of histological necrosis (N-CTav). Next, we confirmed the accuracy of the determined N-CTav in 15 cases with histopathologically proven necrosis in surgical specimens. Furthermore, the percentage of the tumor with N-CTav, i.e., the N-CTav occupancy rate, assessed using Image J software in 30 tumors in 12 patients with CR out of 571 HCC patients treated with lenvatinib, and its correlation with local recurrence following CR were examined. Results: Receiver operating characteristic (ROC) curve analysis revealed an optimal cut-off value of CTav of 30.2 HU, with 90.0% specificity and 65.0% sensitivity in discriminating between pathologically identified necrosis and degeneration, with a CTav of less than 30.2 HU indicating necrosis after lenvatinib treatment (N30-CTav). Furthermore, the optimal cut-off value of 30.6% for the N30-CTav occupancy rate by ROC analysis was a significant indicator of local recurrence following CR with 76.9% specificity and sensitivity (area under the ROC curve; 0.939), with the CR group with high N30-CTav occupancy (≥30.6%) after lenvatinib treatment showing significantly lower local recurrence (8.3% at 1 year) compared with the low (<30.6%) N30-CTav group (p < 0.001, 61.5% at 1 year). Conclusion: The cut-off value of 30.2 HU for CTav (N30-CTav) might be appropriate for identifying post-lenvatinib necrosis in HCC, and an N30-CTav occupancy rate of >30.6% might be a predictor of maintenance of CR. Use of these indicators have the potential to impact systemic chemotherapy for HCC.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N